According to a story from Targeted Oncology, the US Food and Drug Administration (FDA) has granted Fast Track designation to the experimental drug OMP-305B83, also known as navicixiumab. This designation…
GlaxoSmithKline (GSK) has just announced that Zejula, otherwise known as niraparib, has just been approved for cancer patients beyond those who have a BRCA+ mutation. The patients now included in…
According to a publication from OncLive, the Food and Drug Administration (FDA) recently granted priority review status to a supplemental biologics license application for Zejula. Zejula (generic name niraparib) is…
According to a story from BioPortfolio, the biopharmaceutical company Clovis Oncology, Inc. recently released data from a phase 3 clinical trial of patients with recurrent ovarian cancer taking the company's…
According to a story from The Del Mar Times, the Susan Poorman Blackie Ovarian Cancer Foundation (SPB Foundation) and the Clearity Foundation have recently partnered in order to facilitate a…
According to a story from finanzen.ch, the drug companies Pfizer and Merck recently released a joint statement in which they announced that the companies' Phase III clinical trial would be…
According to a story from rdmag.com, a recent study is offering a possible solution to one of the difficulties in treating ovarian cancer. This difficulty is the fact that many…
According to a story from yahoo.com, actress Kathy Bates realized when she was fairly young that she was at an increased risk for breast cancer. This was because both her…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
